Herpes vs Cancer
A newly approved oncolytic immunotherapy takes on cancer using a live modified herpes virus
Stephanie Sutton |
A new drug for an aggressive form of skin cancer has been approved by the FDA, and recommended for approval by the EMA. The therapy has caused a bit of a buzz because it’s the first of its kind in a drug class known as oncolytic immunotherapies; the drug – Imlygic (talimogene laherparepvec) – is a live oral herpes virus (herpex simplex virus-1) that has been genetically modified to selectively attack cancer cells without harming normal tissue.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.